Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
A newer version of this guideline has been published: EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma (2025)
- Study type
- Clinical guideline
- Study name
- EHA-ESMO Multiple Myeloma 2021
- Design
- Joint clinical guideline of the European Hematology Association (EHA) and the European Society for Medical Oncology (ESMO) for the diagnosis, treatment and follow-up of multiple myeloma
- Source
- Annals of Oncology · 2021
In plain words
This document is a joint clinical guideline from two European specialist societies (EHA and ESMO) that sets out for doctors how to diagnose, treat and follow up patients with multiple myeloma. This page is only a short introduction to the document and does not describe its recommendations. Each patient's treatment plan should be decided by the treating doctor according to the patient's situation.
Clinical significance and place in guidelines
This guideline is the joint EHA and ESMO clinical reference for the diagnosis, treatment and follow-up of multiple myeloma. The PubMed record has no abstract and does not contain the recommendations, so the practical implications and details of the recommendations must be taken from the full text of the paper and its 2022 corrigendum. Before using it in clinical practice, check whether this guideline is still current relative to newer versions and guidelines.
Limitations
The PubMed record contains neither an abstract nor the text of the recommendations. This card is based only on bibliographic information; the full text must be reviewed to record the recommendations, levels of evidence and grades of recommendation. A corrigendum has also been published for the paper (Ann Oncol. 2022;33(1):117).
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.